Involvement of FAM170B-AS1, Hsa-miR-1202, and Hsa-miR-146a-5p in Breast Cancer

Overview

Journal Cancer Biomark

Publisher Sage Publications

Specialties Biochemistry
Oncology

Date 2024 Jan 22

PMID 38250762

Authors

Ahmed Saeed Abd ELhafeez

Hala Mostafa Ghanem

Menha Swellam

AlShaimaa Mohamed Taha

Affiliations

Soon will be listed here.

Abstract

Background: FAM170B-AS1 is usually expressed low in all organs except for testicular tissues. No study was performed to explore its role in breast cancer (BC). Contradictory results were reported about hsa-miR-1202 and hsa-miR-146a-5p in BC.

Objective: The present study aimed to explore the involvement of FAM170B-AS1 in BC using bioinformatics predictive tools, followed by a practical validation besides exploring the impact of hsa-miR-1202 and hsa-miR-146a-5p in BC.

Methods: This study enrolled 96 female patients with BC, 30 patients with benign breast diseases (BBD), and 25 control subjects. The expressions of circulating FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p were quantified using qRT-PCR. These ncRNAs' associations, predictive, and diagnostic roles in BC were statistically tested. The underlying miRNA/mRNA targets of FAM170B-AS1 in BC were bioinformatically predicted followed by confirmation based on the GEPIA and TCGA databases.

Results: The expression of FAM170B-AS1 was upregulated in sera of BC patients and hsa-miR-1202 was upregulated in sera of BBD and BC patients while that of hsa-miR-146a-5p was downregulated in BC. These FAM170B-AS1 was significantly associated with BC when compared to BBD. FAM170B-AS1 and hsa-miR-1202 were statistically associated with the BC's stage, grade, and LN metastasis. FAM170B-AS1 and hsa-miR-146a-5p gave the highest specificity and sensitivity for BC. KRAS and EGFR were predicted to be targeted by FAM170B-AS1 through interaction with hsa-miR-143-3p and hsa-miR-7-5p, respectively. Based on the TCGA database, cancer patients having mutations in FAM170B show good overall survival.

Conclusions: The present study reported that for the first time, FAM170B-AS1 may be a potential risk factor, predictive, and diagnostic marker for BC. In addition, FAM170B-AS1 might be involved in BC by interacting with hsa-miR-143-3p/KRAS and hsa-miR-7-5p/EGFR through enhancement or repression that may present a new therapeutic option for BC.

References

Matuszyk J . MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy. Mol Med. 2022; 28(1):89. PMC: 9351108. DOI: 10.1186/s10020-022-00516-2. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Tashkandi H, Shah N, Patel Y, Chen H . Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience. 2015; 2(11):924-9. PMC: 4675790. DOI: 10.18632/oncoscience.275. View

Venkatesh J, Wasson M, Brown J, Fernando W, Marcato P . LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett. 2021; 509:81-88. DOI: 10.1016/j.canlet.2021.04.002. View

Long J, Dong L, Chen F, Fan Y . miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells. Oncol Lett. 2019; 17(2):1573-1580. PMC: 6341734. DOI: 10.3892/ol.2018.9769. View

Delas M, Hannon G . lncRNAs in development and disease: from functions to mechanisms. Open Biol. 2017; 7(7). PMC: 5541349. DOI: 10.1098/rsob.170121. View

Du B, Zhang P, Tan Z, Xu J . MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother. 2017; 96:1246-1252. DOI: 10.1016/j.biopha.2017.11.090. View

Zhou Y, Chen X, Zheng Y, Shen R, Sun S, Yang F . Long Non-coding RNAs and mRNAs Expression Profiles of Monocyte-Derived Dendritic Cells From PBMCs in AR. Front Cell Dev Biol. 2021; 9:636477. PMC: 7906227. DOI: 10.3389/fcell.2021.636477. View

Paplomata E, ORegan R . New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag. 2013; 9:27-36. PMC: 3549674. DOI: 10.2147/TCRM.S30349. View

10.

Jiang P, Liang B, Zhang Z, Fan B, Zeng L, Zhou Z . MicroRNA-146a-5p induces cell cycle arrest and enhances apoptosis in gastric cancer via targeting CDC14A. Front Cell Dev Biol. 2023; 11:1181628. PMC: 10232853. DOI: 10.3389/fcell.2023.1181628. View

11.

Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C . Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. 2019; 9:354. PMC: 6513966. DOI: 10.3389/fonc.2019.00354. View

12.

Wang Z, Zhang H, Zhang P, Li J, Shan Z, Teng W . Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 2013; 30(2):577. DOI: 10.1007/s12032-013-0577-9. View

13.

Mi J, Zhang H, Cao W, Yuan C . FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer. Medicine (Baltimore). 2023; 102(42):e35361. PMC: 10589555. DOI: 10.1097/MD.0000000000035361. View

14.

Shao Y, Sun X, He Y, Liu C, Liu H . Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One. 2015; 10(7):e0133830. PMC: 4514648. DOI: 10.1371/journal.pone.0133830. View

15.

Lu L, Wang J, Wu Y, Wan P, Yang G . Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling. Cancer Med. 2016; 5(12):3544-3554. PMC: 5224839. DOI: 10.1002/cam4.946. View

16.

Hamam R, Ali A, Alsaleh K, Kassem M, Alfayez M, Aldahmash A . microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016; 6:25997. PMC: 4867432. DOI: 10.1038/srep25997. View

17.

Liang H, Huang W, Wang Y, Ding L, Zeng L . Overexpression of MiR-146a-5p Upregulates lncRNA HOTAIR in Triple-Negative Breast Cancer Cells and Predicts Poor Prognosis. Technol Cancer Res Treat. 2019; 18:1533033819882949. PMC: 6826924. DOI: 10.1177/1533033819882949. View

18.

Yamada Y, Yasukochi Y, Kato K, Oguri M, Horibe H, Fujimaki T . Identification of 26 novel loci that confer susceptibility to early-onset coronary artery disease in a Japanese population. Biomed Rep. 2018; 9(5):383-404. PMC: 6201041. DOI: 10.3892/br.2018.1152. View

19.

Rahimi A, Sedighi R, Emadi-Baygi M, Honardoost M, Mowla S, Khanahmad H . Bioinformatics prediction and experimental validation of a novel microRNA: hsa-miR-B43 within human CDH4 gene with a potential metastasis-related function in breast cancer. J Cell Biochem. 2019; 121(2):1307-1316. DOI: 10.1002/jcb.29367. View

20.

Duffy M . Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem. 2006; 52(3):345-51. DOI: 10.1373/clinchem.2005.059832. View